• Verana Health

  Led · Series E · Jan 2022

  Verana Health aggregates de-identified electronic health record data from more than 20,000 clinicians to create high-quality real-world evidence datasets for the life-sciences industry. Its AI-powered curation technology structures and validates data in ophthalmology, urology, and neurology, and, through its merger with COTA, now expands deeply into oncology. The combined company accesses more than 95 million patient records, including over 10 million oncology patients, and partners with an extended network of 30+ academic medical centers. These datasets support biopharma customers across clinical trial design, regulatory submissions, health economics and outcomes research, and market-access work, while also offering advisory services for clinicians’ MIPS submissions. The integration of COTA’s high-fidelity oncology data is expected to speed up data processing and deliver ready-to-analyze datasets to research teams. Verana Health currently serves 17 of the world’s top 20 biopharma companies, underscoring strong commercial traction. The newly raised capital will fund platform expansion and deeper clinical data capabilities. No revenue figures or profitability metrics were disclosed in the article.

• AMSilk

  Led · Series C · May 2021

  AMSilk develops advanced biomaterials from silk-based proteins using a patented technology platform and a supporting patent portfolio. It converts man-made proteins into formulations including fibers and yarns, hydrogels, and silk powder. The company’s high-performance materials target applications across the textile, homecare, biomedical, and automobile industries. AMSilk has collaborated with global companies and intends to continue partnering with enterprises worldwide. The company plans to use the new funds to build further commercial traction and to support the next phase of industrial scale-up to meet growing global demand. The raise followed an extension of its Series C financing in 2023. AMSilk produces bio-fabricated silk protein materials using a patented biotechnological process, converting plant-based renewable inputs into powders, hydrogels, fibers, and coatings. Its materials are 100% protein, do not involve natural farming processes, and are fully biodegradable under aerobic and marine conditions without generating microplastics. The company plans to use the new funding to accelerate industrial scale-up and expand commercial operations for its biotech materials. AMSilk raised an additional €25M in a Series C extension, bringing the total Series C to €54M. The extension was led by ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. Since a €29M financing in 2021, AMSilk has invested in partnership agreements and supply contracts with leading apparel, medical, automotive, and biotech companies. AMSilk is an industrial supplier of synthetic silk biopolymers based in Planegg, near Munich, Germany. Its products are produced from plant-based raw material via bacterial fermentation and possess mechanical and biochemical properties suitable for multiple industries. The company offers high-performance Biosteel® fibers for textiles and industrial applications worldwide and cites use cases in medical devices and personal care products. AMSilk has announced collaborations and partnerships with brands like Adidas and Airbus. Led by CEO Ulrich Scherbel, the company plans to accelerate scale-up of its industrial projects and internationalize commercial activities to expand its customer base into new markets. It raised €29M in a Series C round to fund these efforts. AMSilk produces and processes SPIDERSILK biopolymers copied from the proteins of web-weaving spiders. These biopolymers enable new technical products and improvements to existing products. According to the company, the materials offer mechanical toughness, chemical resistance and biocompatibility while being completely biodegradable. AMSilk completed a €5m Series B financing and intends to use the capital to expand development and sales efforts for its first spider silk-based products. The company plans to pursue those efforts through partnerships with leading companies across major industries. Founded in 2008 as a spin-off from the Technische Universität München, AMSilk is led by Managing Director Axel Leimer.

• The Protein Brewery

  Led · Series A · Nov 2020

  The Protein Brewery makes Fermotein, a mycelium-derived mycoprotein powder produced via non-sterile biomass fermentation of a Rhizomucor pusillus strain. The company highlights that its strain cannot produce mycotoxins and that its high-temperature, low-pH, non-sterile process yields lower capital and operating costs versus other fermentation approaches. It plans to supply about 600 metric tons from its demo-scale factory in Breda in 2027 and scale production capacity to more than 2,000 tons by 2029. The firm is pursuing commercial traction in Europe, Singapore and the U.S., with sales push into Europe planned for Q3 and first U.S. products expected in late 2026. The Protein Brewery is funding human clinical studies, including a large study with Wageningen University on biomarkers of aging in Q1 2027, and is updating regulatory submissions globally while addressing FDA feedback on its GRAS filing.

• Mission Bio

  Led · Series C · Aug 2020

  Mission Bio, based in South San Francisco, offers the Tapestri Platform for single-cell multi-omics and is known for generating DNA and protein data from the same cell. The company recently added targeted gene expression analysis and launched a Single-Cell Targeted Genotype and Gene Expression assay that profiles DNA and RNA from over 10,000 single cells in one assay. Mission Bio plans to broaden the platform to full tri-omics—simultaneous profiling of DNA, RNA, and protein—to support applications including patient stratification, safety assessments, and high-resolution MRD assays. The company reports strong traction with biopharma customers and industry partnerships, including a collaboration with Integrated DNA Technologies (IDT), and intends to expand commercial reach via distribution agreements. Mission Bio also expanded its commercial leadership by appointing Matthew H. Cato as Chief Commercial Officer. Recent equity financing will fund continued platform innovation, commercial growth, and accelerated clinical adoption across multiple cancer segments. Mission Bio develops the Tapestri single-cell multi-omics platform that measures DNA and protein changes within the same single cell to link genotype and phenotype. The platform is used to optimize clinical trials for targeted, precision cancer therapies and to validate genome-editing outcomes. Tapestri’s single-cell resolution helps rule out confounding effects that appear in bulk analyses, improving assessment of therapeutic impact. The company’s technology has been used by pharmaceutical and therapeutic companies (including Agios, LabCorp and Onconova Therapeutics) and at major cancer research centers such as UCSF, Stanford and Memorial Sloan Kettering. Mission Bio intends to scale the Tapestri platform to expand its use in clinical trials and genome-editing validation. The company has raised capital to date to support that scaling effort. Mission Bio is a South San Francisco–based single-cell DNA analysis and precision genomics company spun out of research at the University of California, San Francisco and led by CEO Charlie Silver. Its core product is the Tapestri® Platform, a targeted single-cell DNA sequencing platform that enables detection of heterogeneity in disease progression and treatment response. The Tapestri platform comprises an instrument, consumables, and analysis software that integrate with existing NGS workflows. Application areas include blood cancers, solid tumors, and genome editing validation. The company intends to use new funds to scale Tapestri by expanding the market for blood cancer research, broadening its scope to CRISPR applications, and extending into global markets. Mission Bio has raised more than $50M in total funding. Mission Bio is a South San Francisco developer of single-cell DNA analysis technology and the Tapestri precision genomics platform. Tapestri combines an instrument, consumables and software using proprietary droplet microfluidics to provide DNA accessibility at the single-cell level. The platform has throughput up to 10,000 cells, enabling detection of genomic variability within and across cell populations to support precision medicine research and clinical applications. Led by CEO Charlie Silver and based on Adam Abate's work at UCSF, Mission Bio intends to launch Tapestri and ship its first AML application in December 2017. With Series A funding, the company began a Custom Panel Grant Program to fund researchers building custom panels and will accept commercial panel orders in the first half of 2018. Mission Bio has secured NIH and NSF grants and won industry awards including the QB3@953 Amgen Golden Ticket and the CYTO Innovation Award in 2016. Mission Bio is developing a proprietary microfluidic, droplet‑based platform for high‑throughput single‑cell nucleic acid characterization. Its tools target research applications in oncology and immunology where cellular heterogeneity is critical. The company aims to commercialize a single‑cell genomics system for academic researchers as well as pharmaceutical and biotech customers to enable precision biology. Mission Bio spun out of UCSF three years ago and has received NIH and NSF grants. It has also won awards including the QB3@953 Amgen Golden Ticket and the CYTO Innovation Award. Earlier seed funding came from Tech Coast Angels, Keiretsu Forum and other seed‑stage investors; the company recently secured additional seed investment from Life Science Angels to support commercialization.

• Archimedes Pharma

  Led · Equity · Mar 2010

  Archimedes Pharma is a Reading, UK-based biopharma focusing on oncology, pain, neurology and critical care. It currently markets a range of products in the UK, France, Germany and Ireland and plans to expand commercial presence in Spain and the US during 2010. The company is preparing the global commercial launch of PecFent (previously NasalFent), an innovative fentanyl nasal spray for the treatment of breakthrough cancer pain; PecFent has been filed for approval in Europe and the US and was expected to be approved for commercial sale during 2010. The product is supported by an extensive phase III clinical programme that met all primary and secondary end-points, showing onset of pain relief within five minutes, statistically significant improvements versus immediate-release morphine, high patient acceptability, and consistent effectiveness. Archimedes raised £65m in new funding to establish US operations and support growth of its specialty pharma business in Europe and the global launch of PecFent. The company appointed Jeffrey H. Buchalter as President and CEO and expanded its board to include representatives from Warburg Pincus and Novo A/S.

No current team members are available.